The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A first-in-human study of AMG 780, an angiopoietin-1 and -2 (ANG1/2) inhibitor, in patients (pts) with advanced solid tumors.
Afshin Dowlati
No relevant relationships to disclose
Gordana Vlahovic
No relevant relationships to disclose
Ronald B. Natale
No relevant relationships to disclose
Erik Rasmussen
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Indrajeet Singh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Yuying C. Hwang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
John Rossi
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Michael B. Bass
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Gregory R. Friberg
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Cheryl Ann Pickett-Gies
Employment or Leadership Position - Amgen
Stock Ownership - Amgen